Regadenoson

Regadenoson

Systematic (IUPAC) name
2-{4-[(methylamino)carbonyl]- 1H-pyrazol-1-yl}adenosine
Clinical data
AHFS/Drugs.com	Multum Consumer Information
Licence data	US FDA:link
Pregnancy category	US: C (Risk not ruled out)
Legal status	US: ℞-only
Routes of administration	Intravenous
Identifiers
CAS Number	313348-27-5 Y Template:CAS
ATC code	C01EB21 (WHO)
PubChem	CID: 219024
IUPHAR/BPS	5596
DrugBank	DB06213 N
ChemSpider	189859 N
UNII	7AXV542LZ4 N
KEGG	D05711 Y
ChEMBL	CHEMBL1201750 N
Synonyms	1-[6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]- N-methylpyrazole-4-carboxamide
Chemical data
Formula	C15H18N8O5
Molecular mass	390.354 g/mol
SMILES CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N
InChI InChI=1S/C15H18N8O5/c1-17-13(27)6-2-19-23(3-6)15-20-11(16)8-12(21-15)22(5-18-8)14-10(26)9(25)7(4-24)28-14/h2-3,5,7,9-10,14,24-26H,4H2,1H3,(H,17,27)(H2,16,20,21)/t7-,9-,10-,14-/m1/s1 N Key:LZPZPHGJDAGEJZ-AKAIJSEGSA-N N
NY (what is this?)  (verify)

Regadenoson (INN, code named CVT-3146) is an A_2A adenosine receptor agonist that is a coronary vasodilator that is commonly used in pharmacologic stress testing. It produces hyperemia quickly and maintains it for a duration that is useful for radionuclide myocardial perfusion imaging. The selective nature of the drug makes it preferable to other stress agents such as adenosine, which are less selective and therefore cause more side-effects.

Regadenoson was approved by the United States Food and Drug Administration on April 10, 2008 and is marketed by Astellas Pharma under the tradename Lexiscan. It is approved for use in the European Union and under the name of Rapiscan. It is currently being marketed by GE Healthcare and is being sold in both the United Kingdom and Germany.

Regadenoson has a 2 to 3 minute biological half-life, as compared with adenosine's 10-second half-life. As a result, regadenoson stress protocols use a single bolus, instead of a 4-6 minute continuous infusion, which was needed with adenosine. Another difference is that adenosine infusion is weight based (140mcg/kg/minute), while with regadenoson, a 0.4mg/5mL preloaded syringe dose is standard for all weights. Regadenoson stress tests are not affected by the presence of beta blockers, as regadenoson vasodilates via the adenosine pathway without stimulating beta adrenergic receptors.